US FDA Panel Nod For Teplizumab To Delay Type 1 Diabetes Comes On Strength Of Single Study

 
• By Sue Sutter
  
Boy with insulin
The panel majority found sufficient evidence that teplizumab delays the onset of type 1 diabetes. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers